Jun 1, 2026
157‑patient trial: personalized mRNA vaccine (intismeran) plus pembrolizumab reduced melanoma recurrence and improved five‑year survival
A multicenter clinical trial enrolling 157 patients in Australia and the U.S. tested a personalized mRNA cancer vaccine (intismeran, developed by Moderna) given toge...
